Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study May 2, 2022
Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment Apr 13, 2022
Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic Apr 6, 2022
Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent & Trademark Office Mar 22, 2022
Propanc Biopharma’s CEO Believes Proenzyme Therapy May Become the Healthcare Solution of Choice for Treating Cancerous Solid Tumors Mar 16, 2022
Propanc Biopharma’s Cancer Stem Cell Technology Offers Renewed Hope to Achieve a Total Victory Against Metastatic Cancer Mar 2, 2022
Propanc Biopharma’s Joint Research Partnership with the Universities of Jaén and Granada Enters 13th Year Feb 23, 2022
